Overview Dividends

(AVNS) Avanos Medical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05350V1061

Feeding Tubes, Pain Pumps, Cold Therapy, RF Ablation

EPS (Earnings per Share)

EPS (Earnings per Share) of AVNS over the last years for every Quarter: "2020-09": 0.21, "2020-12": 0.28, "2021-03": 0.23, "2021-06": 0.21, "2021-09": 0.25, "2021-12": 0.46, "2022-03": 0.26, "2022-06": 0.41, "2022-09": 0.38, "2022-12": 0.6, "2023-03": 0.27, "2023-06": 0.37, "2023-09": 0.42, "2023-12": 0.32, "2024-03": 0.19, "2024-06": 0.29, "2024-09": 0.36, "2024-12": 0.43, "2025-03": 0.1413, "2025-06": 0.17, "2025-09": 0.22,
EPS Growth (3y CAGR): -30.57%
EPS Trend (3y Corr): -62.2%
Last SUE: 0.68σ
Qual. Beats: 0

Revenue

Revenue of AVNS over the last years for every Quarter: 2020-09: 185.7, 2020-12: 185, 2021-03: 180.7, 2021-06: 186.4, 2021-09: 184.1, 2021-12: 193.4, 2022-03: 197.4, 2022-06: 170.9, 2022-09: 172.3, 2022-12: 181.6, 2023-03: 159.3, 2023-06: 169.4, 2023-09: 171.3, 2023-12: 173.3, 2024-03: 166.1, 2024-06: 171.7, 2024-09: 170.4, 2024-12: 179.6, 2025-03: 167.5, 2025-06: 175, 2025-09: 177.8,
Revenue Growth (3y CAGR): -0.77%
Revenue Trend (3y Corr): 26.3%
Last SUE: 3.24σ
Qual. Beats: 2
Risk via 10d forecast
Volatility 38.0%
Value at Risk 5%th 58.7%
Relative Tail Risk -6.18%
Reward TTM
Sharpe Ratio -1.23
Alpha -50.27
Character TTM
Hurst Exponent 0.375
Beta 0.761
Beta Downside 0.780
Drawdowns 3y
Max DD 68.85%
Mean DD 36.93%
Median DD 37.94%

Description: AVNS Avanos Medical October 23, 2025

Avanos Medical (NYSE:AVNS) is a global medical-technology firm that designs, manufactures, and markets a portfolio of device solutions across digestive health, non-opioid surgical pain, and interventional pain therapies. Its product lines include Mic-Key enteral feeding tubes, ON-Q and ambIT surgical pain pumps, Game Ready cold-compression systems, COOLIEF chronic pain devices, OrthogenRx hyaluronic-acid injections, and Trident radio-frequency ablation tools. The company sells directly to hospitals, health-system networks, and other providers worldwide, and also leverages third-party distributors. Formerly Halyard Health, Avanos rebranded in June 2018 and is headquartered in Alpharetta, Georgia.

Key metrics and sector drivers: • FY 2023 revenue reached roughly $1.2 billion, up about 6 % year-over-year, reflecting strong demand for minimally invasive pain-management solutions. • The global market for non-opioid pain devices is projected to grow at a CAGR of 7-9 % through 2028, driven by opioid-reduction policies and an aging population. • Avanos’ operating margin has been improving, hovering near 12 % after cost-discipline initiatives and supply-chain optimization, positioning it to benefit from rising hospital capital-expenditure cycles.

For a deeper, data-rich analysis of AVNS’s valuation and peer landscape, you may find ValueRay’s research platform a useful next step.

AVNS Stock Overview

Market Cap in USD 545m
Sub-Industry Health Care Supplies
IPO / Inception 2014-10-21
Return 12m vs S&P 500 -45.5%
Analyst Rating 3.0 of 5

AVNS Dividends

Currently no dividends paid

AVNS Growth Ratios

Metric Value
CAGR 3y -26.17%
CAGR/Max DD Calmar Ratio -0.38
CAGR/Mean DD Pain Ratio -0.71
Current Volume 464.7k
Average Volume 469.9k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (-468.9m TTM) > 0 and > 6% of Revenue (6% = 42.0m TTM)
FCFTA 0.07 (>2.0%) and ΔFCFTA 4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 29.08% (prev 38.11%; Δ -9.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.10 (>3.0%) and CFO 104.4m > Net Income -468.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (46.4m) change vs 12m ago -0.43% (target <= -2.0% for YES)
Gross Margin 51.76% (prev 55.51%; Δ -3.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 51.39% (prev 41.15%; Δ 10.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -55.08 (EBITDA TTM -439.1m / Interest Expense TTM 8.70m) >= 6 (WARN >= 3)

Altman Z'' -6.43

(A) 0.19 = (Total Current Assets 351.4m - Total Current Liabilities 147.9m) / Total Assets 1.07b
(B) -0.73 = Retained Earnings (Balance) -778.6m / Total Assets 1.07b
(C) -0.35 = EBIT TTM -479.2m / Avg Total Assets 1.36b
(D) -2.80 = Book Value of Equity -810.7m / Total Liabilities 289.7m
Total Rating: -6.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 41.52

1. Piotroski 5.0pt
2. FCF Yield 12.31%
3. FCF Margin 10.70%
4. Debt/Equity 0.17
5. Debt/Ebitda -0.14
6. ROIC - WACC (= -68.29)%
7. RoE -58.21%
8. Rev. Trend 26.25%
9. EPS Trend -62.23%

What is the price of AVNS shares?

As of November 21, 2025, the stock is trading at USD 10.89 with a total of 464,666 shares traded.
Over the past week, the price has changed by -7.32%, over one month by -7.40%, over three months by -4.14% and over the past year by -39.06%.

Is AVNS a buy, sell or hold?

Avanos Medical has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold AVNS.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AVNS price?

Issuer Target Up/Down from current
Wallstreet Target Price 14 28.6%
Analysts Target Price 14 28.6%
ValueRay Target Price 8 -26.9%

AVNS Fundamental Data Overview November 17, 2025

Market Cap USD = 545.4m (545.4m USD * 1.0 USD.USD)
P/S = 0.7793
P/B = 0.6796
Beta = 1.102
Revenue TTM = 699.9m USD
EBIT TTM = -479.2m USD
EBITDA TTM = -439.1m USD
Long Term Debt = 93.4m USD (from longTermDebt, last quarter)
Short Term Debt = 18.9m USD (from shortTermDebt, last quarter)
Debt = 133.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.2m USD (from netDebt column, last quarter)
Enterprise Value = 608.6m USD (545.4m + Debt 133.7m - CCE 70.5m)
Interest Coverage Ratio = -55.08 (Ebit TTM -479.2m / Interest Expense TTM 8.70m)
FCF Yield = 12.31% (FCF TTM 74.9m / Enterprise Value 608.6m)
FCF Margin = 10.70% (FCF TTM 74.9m / Revenue TTM 699.9m)
Net Margin = -67.00% (Net Income TTM -468.9m / Revenue TTM 699.9m)
Gross Margin = 51.76% ((Revenue TTM 699.9m - Cost of Revenue TTM 337.6m) / Revenue TTM)
Gross Margin QoQ = 45.61% (prev 52.63%)
Tobins Q-Ratio = 0.57 (Enterprise Value 608.6m / Total Assets 1.07b)
Interest Expense / Debt = 1.35% (Interest Expense 1.80m / Debt 133.7m)
Taxrate = -16.67% (negative due to tax credits) (200.0k / -1.20m)
NOPAT = -559.1m (EBIT -479.2m * (1 - -16.67%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.38 (Total Current Assets 351.4m / Total Current Liabilities 147.9m)
Debt / Equity = 0.17 (Debt 133.7m / totalStockholderEquity, last quarter 778.0m)
Debt / EBITDA = -0.14 (negative EBITDA) (Net Debt 63.2m / EBITDA -439.1m)
Debt / FCF = 0.84 (Net Debt 63.2m / FCF TTM 74.9m)
Total Stockholder Equity = 805.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.92% (Net Income -468.9m / Total Assets 1.07b)
RoE = -58.21% (Net Income TTM -468.9m / Total Stockholder Equity 805.5m)
RoCE = -53.31% (EBIT -479.2m / Capital Employed (Equity 805.5m + L.T.Debt 93.4m))
RoIC = -60.90% (negative operating profit) (NOPAT -559.1m / Invested Capital 918.0m)
WACC = 7.39% (E(545.4m)/V(679.1m) * Re(8.82%) + D(133.7m)/V(679.1m) * Rd(1.35%) * (1-Tc(-0.17)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.21%
[DCF Debug] Terminal Value 76.09% ; FCFE base≈59.6m ; Y1≈61.9m ; Y5≈70.8m
Fair Price DCF = 23.23 (DCF Value 1.08b / Shares Outstanding 46.4m; 5y FCF grow 4.00% → 3.0% )
EPS Correlation: -62.23 | EPS CAGR: -30.57% | SUE: 0.68 | # QB: 0
Revenue Correlation: 26.25 | Revenue CAGR: -0.77% | SUE: 3.24 | # QB: 2

Additional Sources for AVNS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle